Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
January 02, 2019 16:15 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company...
Dova Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2018 16:15 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (Nasdaq: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases...
Dova Pharmaceuticals Announces Management Changes
December 17, 2018 07:30 ET
|
Dova Pharmaceuticals, Inc.
Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of...
Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results
November 08, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
Third quarter net product sales of $2.9 million from DOPTELET® (avatrombopag); 335 cumulative unique prescribers from launch through September 30, 2018 sNDA accepted for review by FDA for DOPTELET...
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
November 06, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor...
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
November 05, 2018 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases...
Dova Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 8, 2018
November 01, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Thursday, November 8, 2018 at 4:30 p.m. ET to discuss third quarter 2018...
CORRECTING and REPLACING – Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
September 27, 2018 11:57 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), please note...
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
September 27, 2018 07:45 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and...
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
September 26, 2018 16:15 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...